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ABSTRACT: Identification of metabolites in large-scale 1H NMR data from
human biofluids remains challenging due to the complexity of the spectra and their
sensitivity to pH and ionic concentrations. In this work, we tested the capacity of
three analysis tools to extract metabolite signatures from 968 NMR profiles of
human urine samples. Specifically, we studied sets of covarying features derived
from principal component analysis (PCA), the iterative signature algorithm (ISA),
and averaged correlation profiles (ACP), a new method we devised inspired by the
STOCSY approach. We used our previously developed metabomatching method to
match the sets generated by these algorithms to NMR spectra of individual
metabolites available in public databases. On the basis of the number and quality of
the matches, we concluded that ISA and ACP can robustly identify ten and nine
metabolites, respectively, half of which were shared, while PCA did not produce any signatures with robust matches.
KEYWORDS: 1D NMR automated analysis, metabolite identification, modular analysis, STOCSY, ISA, pseudoquantification,
NMR spectroscopy, untargeted metabolomics
■ INTRODUCTION
Nuclear magnetic resonance (NMR) spectroscopy is a powerful
technique for metabolomic profiling. NMR spectroscopy does
not consume the sample and has high accuracy and
reproducibility. Single proton NMR spectroscopy (1H NMR)
can be used to generate one-dimensional spectra of biofluids at
high throughput and low cost, facilitating the generation of large
sets of spectral data.
A first step in NMR spectral analysis is usually to identify the
mainmetabolites giving rise to a given spectrum or set of spectra.
This is nontrivial, since human biofluids typically contain a large
number of individual metabolites and their corresponding peak
positions may overlap and are often affected by the pH, ionic
strength, and overall protein content of the fluid.
For small sets of samples, expert analysis is therefore still the
most accurate means for metabolite identification, yet for large
sets this approach is costly, time-consuming, and potentially less
reproducible. As a result, various methods have been suggested
to assist or fully automate metabolite identification.
In their landmark paper on statistical total correlation
spectroscopy (STOCSY), Cloarec et al. showed that analyzing
the correlation patterns between features across a sizable
collection of 1H NMR spectra has great potential for metabolite
identification.1 This is because features corresponding to the
same molecule (or molecules whose concentrations covary)
tend to be significantly correlated in large data sets. Analyzing
data from 612 mouse urine samples, they observed that the
correlation matrix exhibited correlated peaks of features
characteristic of valeramide, glucose, hippurate, 2-oxoglutarate,
3-hydroxyphenylpropionate, citrate, as well as methylamine,
dimethylamine, and trimethylamine.
Subsequent variations of STOCSY attempted to make
clusters of NMR peaks to simplify the interpretation of the
information stored in the correlation matrix from STOCSY
analysis. Recoupled-STOCSY (R-STOCSY) employs a variable
size bucketing method to reduce the dimensionality of NMR
data and statistical recoupling of variables (SRV) to identify
correlations between distant clusters.2 Iterative-STOCSY (I-
STOCSY) aims at separating the intermetabolite connections
from intrametabolite connection by recursively applying
STOCSY analysis first from a selected driver peak and then for
all peaks correlating with the driver peak above a specific
threshold.3 Subset optimization by reference matching
(STORM) selects subsets of 1H NMR spectra that contain
specific spectroscopic signatures of biomarkers differentiating
between different human populations.4
Once metabolite identification has been achieved, the next
challenge is to quantify metabolite concentrations. This process
works robustly only for a relatively small set of metabolites, and
requires expert refinement when using publicly available
quantification tools such as BATMAN,5 FOCUS,6 BAYESIL,7
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ASICS,8 AQuA,9 or rDolphin.10 This is unsatisfactory in light of
the fact that a sizable number of metabolites have been identified
in human biofluids. For example, the latest version of theHuman
Metabolome Database (HMDB 4.0)11 includes more than 1500
metabolites with 1H NMR spectra, 179 of which have been
identified in urine12 and 67 in serum.13,14
There are several reasons why it remains difficult to perform
fully automated quantification from large-scale NMR data for
the vast majority of metabolites. First, human biofluids contain a
large number of individual metabolites whose concentrations
vary across several orders of magnitude. This makes it difficult to
disentangle the contributions of metabolites with low
concentrations, in particular when their NMR features are not
unique. Second, the exact feature positions depend on the
biofluid and may have been different when acquiring reference
spectra. Third, while the number of reference spectra continues
to grow, reference databases are certainly not yet exhaustive.
In two recent studies, we demonstrated that the limitations of
targeted NMR metabolomics can be addressed by linking
metabolites to external variables.15,16 Specifically, in the context
of genome-wide association studies (GWAS) applied to
metabolomics (known as mGWAS) the aim is to associate
metabolites with genotypic variants. We observed that the effect
of a genetic variant on the concentration of a metabolite often
translates into associations with all or many features of the
metabolite NMR spectrum. The set of association scores with all
measured features provides a pseudospectrum across the full
range of ppm covered by the 1H NMR spectra. The challenge is
then to identify the metabolite underlying the most significant
associations. To this end we developed the analysis tool
metabomatching, which takes as input a pseudospectrum and a
collection of reference spectra for individual metabolites found,
for example, in HMDB.11 Our previous work showed that
metabomatching works well to prioritize the most likely
metabolite candidates for pseudospectra derived from metab-
olome feature association with genotypes.15−17
In the present work, we tested the metabomatching
methodology for identifying metabolites that vary across large
collection of samples without the need for any external variables
associated with this variation. We investigated three methods to
identify covarying spectral features within large-scale NMRdata:
principal component analysis (PCA), the iterative signature
algorithm (ISA), and averaged correlation profiles (ACP)
inspired by the STOCSY approach. For each method, we
devised a principled way for processing their output into
pseudospectra. In addition, we extended metabomatching to
process the respective outputs of the methods, and implemented
a permutation-based robustness test to assess the quality of the
matches. This allowed us to compare the matches across
different methods, and assess the consistency or complemen-
tarity of the methods. We incorporated our analysis for
unsupervised generation of metabolomic signatures from
large-scale NMR data and integration with metabomatching
(including further documentation) into the metabomodules
software tool, which is publicly available at https://github.com/
BergmannLab/metabomodules-docker.
■ METHODS
Preprocessing
For this study, we used 968 1H NMR spectra acquired from
urine samples from the CoLaus cohort.15 The samples are
referenced to the TSP signal, phase-corrected, and baseline-
corrected.
We used the FOCUS6 tool to align and bin the spectra to a
resolution of about 0.02 ppm, and a correspondingly large
number of 687 peaks. To obtain this resolution, we set the
downsampling frequency parameter window.fs to 1 (no down-
sampling), the sliding window length for spectral segmentation
window.length to 0.03 ppm, the minimum peak width parameter
peak.DFL to 0.02 ppm, and the peak sample frequency
parameter peak.pS to 0.2, keeping the rest of the parameters at
their default values.
To normalize the data, we log-transformed, standardized
across features (thereby normalizing the concentration of each
sample), then standardized across samples (thereby making
intensities comparable).
Confounding
In order to allow for the identification of metabolites that may be
hidden by confounding, we additionally generated a data set of
residuals, created by regressing out the confounders from the
feature metabolome. The main confounding factors of the NMR
data that we investigated here are age, sex, serum creatinine, and
urine creatinine.15,16
Metabomatching
Our original metabomatching method was designed to match
the NMR spectra of individual metabolites recorded in a
database with pseudospectra from the association between
metabolome features and an external variable, typically a SNP
genotype. For a metabolite m, metabomatching computes the
sum
s F z( )m
f F
f
2
m
∑=
∈ (1)
where Fm is the set ofNf features that fall within a neighborhood
of any peak of m according to the database, and zf denotes the
significance value for feature f, and is given by zf = β̂f/SEf ̂ , where
β̂f and SEf ̂ refer to the point estimates of the effect size and its
standard error, respectively. Under the null hypothesis of
normally and independently distributed zf, the sum s follows a
χ2-distribution withNf degrees of freedom, andmetabomatching
defines the score for m as the negative logarithm of the nominal
p-value for the sum. This score is then used to rank all tested
metabolites as metabolites with more similar NMR spectra to a
given pseudospectrum achieve higher scores.
In addition to pseudospectra from regression analysis,
provided as columns headed by beta, se, and p, we extended
metabomatching to accept pseudospectra produced by PCA,
ACP, and ISA as columns headed by pca, cr, and isa respectively.
For ACP pseudospectra, metabomatching translates a correla-
tion c to a z-score with the Fisher transformation z = λ
arctanh(c). For independent features, N 3λ = − produces z-
scores with unit standard deviation, where N is the number of
samples across which the correlations are computed. However,
since proximal features are usually not independent, metab-
omatching allows for a user-provided estimate for λ (obtained
from the pairwise feature−feature correlation matrix), or re-
estimates λ from the given correlations. For ISA and PCA
pseudospectra, metabomatching standardizes the loadings or
module scores.
We used the plus/minus mode of metabomatching since
features are z-scored and have positive and negative signs. This
allows for detecting metabolites corresponding either to the
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negative or positive features (see metabomatching documenta-
tion at https://github.com/rrueedi/metabomatching for more
details).
We also introduced a measure of the quality of a match, which
allows to compare matches between different pseudospectra.
This adjusted score is obtained by reshuffling the pseudospec-
trum, and defining a heuristic p-value by the numberNp of allNr
reshuffled pseudospectra that produce a metabomatching score
(for any reference spectrum) higher than the metabomatching
score of the input pseudospectrum with the highest ranked
reference spectrum. This p-value is defined as (Np + 1)/(Nr + 1),
and the adjusted score as −log(p). We used Nr = 9999, which
sets the upper limit for the adjusted score to 4.
For the reshuffling to be consistent with the structure of NMR
spectra, metabomatching identifies cut points that separate the
pseudospectrum into peak-preserving clusters of features and
only reshuffles these clusters. The cut points are obtained as
follows. Let f i be the positions on the chemical shift axis of the
metabolome features, sorted such that f i < f i+1, and C the set of
cut points. First, metabomatching populates C with features
bordering a gap, that is a region absent from the spectrum and
larger than δgap (i.e., f i > f i−1 + δgap), with δgap = 0.3 ppm as
default value. Next it sorts the remaining features by their
corresponding absolute-valued z-scores. Starting from the
feature with the lowest absolute z-score it adds features to C
provided they have a distance greater than δmin to any features
already assigned to C and an absolute z-score below a threshold
zmin. Default values are 0.04 ppm for δmin and the standard
deviation of all absolute z-scores across the features of a given
pseudospectrum for zmin.
ACP: Averaged Correlation Profile
ACP is a greedy approach to generate a list L of feature pairs and
their corresponding correlation profiles c as input for
metabomatching: (1) We compute and sort all pairwise
correlations Cij between features f i and f j separated by at least
0.1 ppm. (2) Starting with the feature pair P = (i,j) with the
highest correlation, we successively add feature pairs to L unless
there is already a feature pair in L whose features are within 0.1
ppm of f i and f j, respectively. (3) For each feature pair in L, we
define an averaged correlation prof ile as the average of the
correlation profiles of f i and f j: ck = (Cik +Cjk)/2. The correlation
profiles of strongly correlated features are similar, consequently
their average is similar to both of them. Crucially, the average
does not contain an element equal to 1, as ci = cj = (1 +Cij)/2 < 1
given that Cij < 1 in real data. For our analysis, we limit L to 179
averaged correlation profiles, 179 being the number of spectra in
UMDB, the reference database on which metabomatching will
run.
As an alternative approach, we tried agglomerative clustering
of features, iteratively joining features (or sets of features) whose
correlation was above a threshold Cmin. At each step, we
averaged joined (sets of) features into a metafeature and
recomputed its correlation to all remaining (meta)features. We
then built a correlation profile for each feature cluster by
averaging the correlations profiles of the component features.
ISA: Iterative Signature Algorithm
ISA is a biclustering method first developed for modular analysis
of gene expression data.18,19 ISA uses a heuristic iterative
procedure starting with random features to refine modules,
consisting of self-consistent subsets of features and samples.
Each module is defined for a set of two thresholds, determining
how extreme the features and samples are allowed to be.
Importantly, scanning through an array of thresholds usually
identifies a set of modules (or module families) that is smaller
than the number of samples or features.
We first ran the ISA algorithm to generate modules from the
NMR data using the default values for the parameters except the
following: (1) we changed both row and column thresholds
from the default values {1, 2, 3} to {1, 2, 3, 4, 5, 6} to produce
modules containing fewer rows or columns that are more likely
to represent single metabolites, (2) we increased the number of
seeds from 100 to 250, and (3) we lowered the correlation
threshold below which ISA considers two modules equal to one
another from 0.95 to 0.50 to favor diversity in modules.
We allowed feature scores to be either positive or negative,
while sample scores were always positive. This means that
modules can include features which have on average higher or
lower intensities in the selected samples than for the remaining
samples. Modules which include such a mixture are likely to
represent (at least) two metabolites whose concentrations are
inversely related to each other (like a substrate and its product).
This procedure generated 216 modules. To select the 179
modules as an input for metabomatching, we sorted them by the
size of their basin of attraction. Tomeasure the basin size, we ran
ISA a second time with the same parameters, but on 10 000
seeds, turning off the sweeping option, and keeping all converged
modules (by setting the purge option to false). We then assigned
a run 2 module to the basin of the run 1 module with which it
had the highest correlation (provided that correlation be greater
than 0.5). We assumed that the run 1 modules attractor basin
size is approximately equal to the count of modules from run 2
which were assigned to them in the previous step. Finally, we
passed to metabomatching the 179 modules from run 1 with
largest basins.
PCA: Principal Component Analysis
We used the sklearn library for Python (2.7) to compute all
principal components of the preprocessed data. Specifically, we
used the decomposition.PCA object, with n_components set to
687 and svd_solver set to full.
Identification of Metabolites
After running metabomatching on the pseudospectra generated
by ISA, ACP and PCA, we applied a filtering algorithm to select
only the most robust matches among all pseudospectra. The
filtering passes only those pseudospectra which achieve an
adjusted score above 2 with their top metabolite match
(ensuring the pseudospectra finds a reasonable match by
metabomatching) and have at least one peak with z-score above
4 (ensuring there is a strong signal). Note that multiple
pseudospectra can match with the same metabolite NMR
spectrum.
Out of the 179 pseudospectra from ACP, 10 pseudospectra
matching different metabolites passed the filtering. Among
these, only for one pseudospectrum, i.e., 3.87 and 3.75, the top
match to hydroxypropionate (Figure S24) did not look
convincing because of slightly worse matches to mannitol and
arabitol (Figure S24).
Out of the 179 pseudospectra from ISA, 19 pseudospectra
matching different metabolites passed the filtering. Among
these, we discarded 9 for one or more of the following three
reasons: (1) There are several metabolites which all achieve high
adjusted scores (Figures S25 and S26). (2) There is at least one
strong peak in the pseudospectrum that does not match with any
of the spectra of the best matching metabolites (see Figures
S27−S32). This may happen for pseudospectra with a large
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number of peaks. These pseudospectra are not necessarily
biologically irrelevant and might carry a signature for two or
more related metabolites. (3) The pseudospectrum passed the
filtering, yet did not appear to have sufficiently strong signals at
the peak positions of its putative matching metabolites (Figures
S33 and S34).
We analyzed all 687 pseudospectra from PCA and observed
an elevation in metabomatching scores for the last principal
components (all between components #505−687, which jointly
explain only 1% of variation; Figures S1A, S35−S39). However,
since these components explain almost no variation in the
metabolome and the last 9 principal components matched the
same metabolite, hippurate (Figure S1D), we investigated
whether these matches rely on numerical instability. Indeed,
when we removed one feature from all feature pairs that
correlated above 0.95 (i.e., 8 features from 34 feature pairs all
belonging to hippurate multiplets regions 7.54−7.56, 7.63−
7.65, 7.83−7.84, and 3.96 ppm), and ran metabomatching on all
pseudospectra generated from the principal components of the
remaining features, only five passed the filtering (Figure S1F).
However, none of these seemed convincing when applying the
same curation as for the ISA pseudospectra.
Pseudoquantification of Metabolite Concentrations
We use the term pseudoquantification as this approach should
not be confused with traditional quantification approach which
sometimes rely on experiments that target a specific metabolite
and often require the use of proprietary software operated by an
expert.
We perform our pseudoquantification by using discrete
integration to estimate relative metabolite concentrations,
according to
c
K H
I
1 1
i
k
K
k l s r
ij j
1 k j k
∑ ∑= Δ
= ≤ ≤ (2)
where K is the number of multiplets, Hk the number of protons
in multiplet k, [lk, rk] the range of multiplet k, sj the chemical shift
of feature j, Iij the intensity of this feature in individual i, and Δj
the width of the bin at sj. For example, for hippurate K = 4, H =
[2, 2, 1, 2], l = m − 0.025, r = m + 0.025, where m = [3.98, 7.54,
7.65, 7.84]. We then evaluated this relative concentration first
using the peak positions from the reference spectrum as listed in
UMDB, and second using the peak positions as suggested by the
pseudospectrum found by the modular approach.
To perform the pseudoquantification based on the
pseudospectra of the modules, we defined a set of multiplet
positions to use in eq 2 for eachmodule that robustly identified a
metabolite. This set is composed of all the chemical shifts from
the module of interest with z-scores above 3 and within 0.025
ppm of the multiplet positions of the matching metabolite in
reference database. It includes all relevant peaks from the
metabolite detected by the modular analysis.
■ ANALYSIS AND RESULTS
In this work, we show that metabomatching can be used with
pseudospectra capturing the internal structure of large-scale
NMR data rather than their correlation with external variables.
Specifically, our premise is that in sizable sample collections
there is sufficient power for methods identifying coherent
features that may point to the same metabolite.
We used three methods for identifying weighted sets of
covarying spectral features from large-scale NMR data that can
be used as input for metabomatching (see Methods for more
details and Figure 1 for an illustration of the workflow).
Correlation-Based Pseudospectra
Our first approach to select covarying features was to use the
correlations between features across all samples. We faced two
challenges: First, using the correlations of a given feature with all
features as a pseudospectrum would break the scoring algorithm
in metabomatching, due to self-correlation of features that result
in infinite z-scores. Second, as generating only a limited number
of pseudospectra was desired ranking the input sets was
necessary to select only the most relevant ones.
To address these challenges, we devised an algorithm that
ranks all pairs of sufficiently distant features and computes
averaged correlation profiles (ACP) for pairs of highly correlated
features. Strictly speaking, ACPs are not the correlations but
they are the average correlation profiles, with the premise that
for highly correlated feature pairs the correlations to other
features tend to be similar, while none of the averages equals to
one. Within metabomatching these ACPs are then translated
into z-scores using the Fisher z-transformation (seeMethods for
more details). We also tried hierarchical clustering to define
pseudospectra from multiple highly similar features (see
Methods), but this approach did not work as well.
Iterative Signature Algorithm
ISA has been designed for the unsupervised identification of
coherent subsets in large-scale data.18,19 Specifically, coherence
Figure 1.Workflow for unsupervised analysis of large-scale NMR data.
Raw 1H NMR data are normalized then aligned. These processed
profiles are used as input for the averaged correlation profile (ACP),
iterative signature algorithm (ISA), and principal component analysis
(PCA) methods, which output correlation profiles, module scores, and
PCA loadings, respectively. These outputs constitute possible
pseudospectra for metabomatching, which identifies the most plausible
candidate metabolites underlying the coherent feature variations.
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between features is not defined by total correlation across all
samples, but rather by a subset of samples for which a set of
features takes more extreme values than for the rest of the
samples. Such a joint set of features and samples is called a
module. In order to obtain a pseudospectrum for eachmodule we
averaged each feature’s score (whether part of the module or
not) across the samples assigned to the module. These averages
were then transformed into z-scores. By definition the features of
the module have the most extreme z-scores, yet other features
that were just below the threshold may also have a sizable
contribution. We then used these z-scores as input for
metabomatching.
Principal Component Analysis
We also used PCA to compute the loadings of all features onto
the eigenvectors of the sample−sample correlation matrix across
all features. These eigenvectors (or eigensamples) characterize
independent axes of variation in sample space. The correspond-
ing eigenvalues reflect the fraction of total variation explained by
each eigenvector. It was not clear a priori which principal
components might characterize variation due to single
metabolites. We therefore applied metabomatching to all of
them. Specifically, we generated pseudospectra by standardizing
the loadings corresponding to each eigensample (see Methods
for more details).
Many Pseudospectra Defined by the ACP Method and ISA
Match to Urine Metabolites
We observed a trend of elevated metabomatching scores for
pseudospectra corresponding to principal components with
small eigenvalues (starting from component #505), jointly
explaining only 1% of variation (Figure S1A). The last nine
principal components matched to hippurate, but disappeared
when running PCA on the metabolome stripped of features that
are highly correlated to other features (see Methods; Figures
S1D and S1F). Additionally, the adjusted scores of all potential
hits decreased significantly for the stripped metabolome (Figure
S1E). We therefore concluded that PCA is not well-suited for
generating robust metabolite signatures.
In contrast, our ACP method and ISA resulted in a sizable
number of pseudospectra for which metabomatching produced
robust matches to urine metabolites (see Figure 2 and Methods
for details). Specifically, both ACP and ISA identified feature
sets pointing to glucose, citrate, ethanol, hippurate, and P-
hydroxyphenylacetate (Figures S2−S11). Glucose and hippu-
rate were among the metabolites identified by Cloarec et al. with
the correlation matrix of mouse urine NMR data.1
P-hydroxyphenylacetate shares an aromatic ring with 3-
hydroxyphenylpropionate, another metabolite highlighted in
the original STOCSY paper.1 Both compounds are part of
phenylalanine metabolism and occur as products of bacterial
degradation of aromatic compounds. In human urine high
concentrations of these compounds may reflect an overgrown
Clostridium species in gut microbiota, which has been associated
with autism spectrum disorders.20
In healthy humans, urine glucose should be low, but
concentrations may be elevated due to diabetes or chronic
kidney disease (CKD), conditions which are prevalent in the
CoLaus population.
Citrate is an additive commonly used by the food industry and
it is also synthesized as an intermediate product in the
tricarboxylic acid cycle, a central pathway that releases stored
energy from fat, proteins, and carbohydrates. Low urinary citrate
is associated with CKD and kidney stone formation.
There are a number of metabolites that matched to
pseudospectra generated only by one of the two methods.
With ISA, we found modules matching 3-aminoisobutyrate, an
end product of nucleic acid metabolism that has been
considered a potential biochemical marker for cancer21 (Figure
S12); creatinine, a breakdown product of creatine, whose high
and stable concentration in urine is often used for normalization
(Figure S13); lactose (Figure S14); and lactate, the bacterial
breakdown product of lactose (Figure S15). Conversely, ACP
produced correlation profiles matching to taurine (Figure S16),
an organic compound widely distributed in animal tissues and a
major constituent of bile; creatine (Figure S14); oxoglutarate
(α-ketoglutarate), an important biological compound produced
by deamination of glutamate, and an intermediate in the Krebs
cycle (Figure S18); and 3-hydroxyisovalerate, a byproduct of
valine, leucine, and isoleucine degradation and a marker for
biotin deficiency22 (Figure S19). These compounds are all
common urine metabolites that can exist in high concentrations.
Correcting features for significant covariates, both methods
also found set of features matching carnitine, which owes its
name to its high concentration in meat (see Methods for more
details). While it is produced in both animal and plant cells, this
may explain why we could detect its signature in human urine
samples.
Metabolite Concentration Pseudoquantification with NMR
Features of Matched Pseudospectra
We next investigated whether the sets of weightedNMR features
generated by ISA or the ACP method can not only be used to
identify metabolites, but also facilitate their pseudoquantifica-
tion. This pseudoquantification approach aims to estimate the
relative concentration of the metabolites in untargeted 1HNMR
of urine samples. We performed our pseudoquantification by
computing the area under the peak of each multiplet in the
metabolite spectrum using discrete integration, dividing it by the
number of protons associated with the multiplet and then
averaging scaled areas over all multiplets in the metabolite
spectrum (see Methods for more details). We hypothesized that
the leading features selected by our algorithms for a certain
metabolite may be better suited for pseudoquantification than
the full reference spectra from public databases such as UMDB.
There are two possible reasons for this. First, the exact feature
positions extracted from the data by ISA or the ACP method
Figure 2. Urine metabolites that were robustly matched by
metabomatching to pseudospectra derived from average correlation
profiles (ACP, green), the iterative signature algorithm (ISA, blue), or
both methods (black).
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may be more accurate, even if, by design, they fall within the
margin of the matching window of reference spectrum features.
Second, for metabolites with several peaks, only a subset might
have been picked up by these algorithms. Indeed, both ISA and
the ACP method may leave out peaks that did not contribute
coherently to the peak set since their signal was too noisy (e.g.,
due to overlap with those from other metabolites).
We performed our pseudoquantification method (using eq 2
in Methods) to estimate concentrations of glucose and ethanol,
for which relevant phenotypes were available in the cohort. For
urine glucose, the phenotype was fasting blood glucose. For
urine ethanol, relevant biomarkers included serum asialotrans-
ferrin and disialotransferrin, which combined are known as
carbohydrate-deficient transferrin (CDT), a biomarker for
heavy alcohol use. Furthermore, self-reported alcohol con-
sumption was available. These biomarkers were measured in a
different biofluid (i.e., blood), which was collected on the same
day as the urine sample. We argue that detecting significant
correlations between our estimated metabolite concentrations
and these biomarkers provides a proof of concept that our
pseudoquantification is reliable, and comparing correlations
between different pseudoquantification approaches provides a
means to evaluate them.
The 1HNMR spectra of glucose has ninemultiplets. Including
all these multiplets chemical shifts from the UMDB database
(Table 1) to perform pseudoquantification, we obtain a
correlation of 0.46 (with a 95% confidence interval (CI) of
[0.41, 0.52]) between the estimated concentration of urine
glucose and fasting blood glucose. This correlation increases to
0.50 [0.44, 0.55] if the subset of seven multiplets from ISA
module #16 (Figure 3A) is used for pseudoquantification (see
Methods for details). From the 179 ACP pseudospectra, two
robustly matched glucose, one from averaging the correlation
profiles from feature pair 3.48 and 5.24 and another from
averaging correlation profiles from 3.89 and 5.24 (Figure 3B,C),
each capturing four out of nine multiplets of glucose (Table 1).
Using the subset of peaks from 3.48 and 5.24 ACP
pseudospectra we obtain a correlation of 0.48 [0.43, 0.54]
between glucose pseudoquantification and fasting blood glucose
while using the subset of peaks from 3.89 and 5.24 ACP
pseudosspectra a correlation of 0.44 [0.38, 0.49] is obtained.
Combining the peak subsets from both pseudospectra to a
subset of 6 peaks did not improve the correlation beyond 0.48
[0.43, 0.54] (see Table 1 and Methods for more details on peak
sets used for pseudoquantification).
The 1H NMR spectra of ethanol has only two multiplets (as
well as one singlet from the hydroxyl group, which can not be
discerned in water solutions like urine). Using the reference
spectrum from UMDB to perform pseudoquantification, we
obtained a relatively low correlation of 0.29 [0.23, 0.35] between
the estimated concentration of urine ethanol and CDT levels in
serum (Table 1, see Table S1 for other alcohol markers). The
ACP method produced one pseudospectra, 1.18 and 3.67, and
ISA produced two modules (#57 and #240) that metabomatch-
ing matched to ethanol (Figures S6, S7, and S22). The positions
of the ACP peak set (i.e., 1.18 and 3.67) were identical to those
of ISA module #57 and were more similar to the ethanol
spectrum (achieving a higher adjusted score in metabomatch-
ing) than those of ISA module #240 (Figure 3D−F).
Nevertheless, pseudoquantification for the ACP pseudospec-
trum and ISA module #57 yielded a lower correlation of 0.16
[0.10, 0.22] with CDT levels than the UMDB reference peaks
(0.29 [0.23, 0.35]) (Table 1). This is due to a high correlation of
CDT with the features at 1.145−1.155 ppm, which are within a
0.025 ppm neighborhood of the UMDB ethanol peak at 1.17
ppm but not within the same neighborhood of the 1.18 ethanol
peak from ACP and ISA module #57 (Figure S20). Yet, these
peaks at 1.145−1.155 ppm are unlikely to correspond to ethanol,
since their correlation with the other ethanol peak at 3.67 ppm is
much weaker than the correlation between the 1.18 and 3.67
ppm peaks. Instead, they may belong to a different metabolite
whose concentration is correlated with CDT (Figure S21). In
contrast, summing up the intensities over all the features of ISA
module #240 with a z-score above 3 as a pseudoquantification
measure (in the absence of any multiplet information), we
obtained a correlation of 0.51 [0.46, 0.57] with the CDT
measurements.
Table 1. Correlation between Pseudoquantification and Measured Biomarkers of Glucose and Ethanol
urine metabolite feature source multiplet positions (ppm) related biomarker correlation [95% CI]
glucose UMDB 3.23, 3.40, 3.46 serum 0.46
3.52, 3.73, 3.82 glucose [0.41, 0.52]
3.88, 4.63, 5.22
glucose ACP: 3.48 and 5.24 3.40, 3.48, 4.65 serum 0.48
5.24 glucose [0.43, 0.54]
glucose ACP: 3.89 and 5.24 3.82, 3.89, 4.65 serum 0.44
5.24 glucose [0.38, 0.49]
glucose ISA: module #16 3.25, 3.41, 3.48 serum 0.50
3.50, 3.89, 4.65 glucose [0.44, 0.55]
5.24
ethanol UMDB 1.17, 3.65 serum 0.29
CDT [0.23, 0.35]
ethanol ACP: 1.18 and 3.67 1.18, 3.67 serum 0.16
CDT [0.10, 0.22]
ethanol ISA: module #57 1.18, 3.67 serum 0.16
CDT [0.10, 0.22]
EtG Nicholas et al.23 1.24, 3.30, 3.52 serum 0.36
3.71, 3.99, 4.48 CDT [0.30, 0.42]
EtG ISA: module #240 1.24, 3.52, 4.47 serum 0.46
CDT [0.40, 051]
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To better understand why module #240 correlates more
strongly to the alcohol consumption biomarker while being a
worse match to ethanol than module #57 (Figure 3), we studied
whether any of its features point to other compounds related to
ethanol metabolism. Indeed, we found that this module contains
three features, at 1.26, 3.52, and 4.47 ppm, that individually
correlate more strongly to CDT (0.40 [0.34, 0.45], 0.29 [0.23,
0.35], 0.33 [0.27, 0.39], respectively) than the features mapping
to ethanol. Interestingly, these features appeared to be close to
those of ethyl glucuronide (EtG), a direct product of ethanol
nonoxidative metabolism by conjugation with uridine diphos-
phate (UDP)-glucuronic acid, which had previously been
detected in 1H NMR spectra of liver extracts23 and more
recently in human urine of alcohol drinkers.24 To confirm EtG as
a possible match for ISA module #240, we added its features as
extracted from Nicholas et al.23 to the metabomatching library
manually, since EtG had no entry in UMDB. We observed that
ethanol and EtG spectra together provided a better match to ISA
module #240 than ethanol alone (Figure S22). Interestingly, the
distance between the two peaks corresponding to the doublet at
4.48 ppm is about 0.0126 ppm, corresponding to a coupling of
8.8 Hz (for a 700 MHz spectrometer) consistent with the
coupling of 8 Hz reported in Nicholas et al.23 (see Figure S23
and Supporting Informationfor more details).
Performing the pseudoquantification of EtG using the peak
set of 6 reference positions extracted from Nicholas et al.23, we
obtained a correlation of 0.36 [0.30, 0.42] with CDT levels;
performing the pseudoquantification with the 3 feature subset
from module #240, we obtained a correlation of 0.46 [0.40,
0.51] (Table 1). This indicates that EtG pseudoquantification
correlates better with CDT than ethanol, which is in agreement
with the fact that EtG is detectable in urine for a longer time
window (2−5 days) than ethanol (12−24 h), and CDT is a
marker for heavy alcohol use (at least five drinks a day over a
period of 2 weeks before giving the sample25). Remarkably, the
pseudoquantification facilitated by the three features of module
#240 correlates evenmore strongly with CDT than the full set of
EtG reference features, presumably because these features have
the best signal-to-noise ratio and optimal position for our data.
They may therefore constitute a promising urine biomarker for
Figure 3. Pseudospectra from ACP and ISA algorithms matching glucose, ethanol, and EtG. Each plot shows the pseudospectrum in blue in the upper
half and the reference spectrum fromUMDB in black and in the lower half. Dark blue indicates chemical shifts and their±0.025 ppm vicinity that were
used for pseudoquantification.
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heavy alcohol consumption. Indeed, while the correlation
between EtG pseudoquantification and CDT measure increases
to 0.59 [0.46, 0.72] when focusing on subjects who have self-
reported heavy drinking, pseudoquantification of module #240
gives rise to a slightly higher correlation of 0.61 [0.48, 0.74].
■ CONCLUSIONS AND DISCUSSION
In this work, we implemented and tested newmethodologies for
analyzing large-scale 1H NMR spectroscopy data. Building on
previous ideas to use the correlation structure of such data to
generate metabolomic signatures, we investigated three
complementary methods for generating such signatures and
benchmarked the methods in terms of how many of their
signatures matched with reference spectra in public databases.
By design, these approaches will only identify metabolites with
at least two distinct peaks, and therefore complement peak-
picking identification approaches, which tend to focus on single
peak metabolites.
We found that average correlation profiles (ACP) of highly
correlated feature pairs, a method inspired by STOCSY, as well
as the iterative signature algorithm (ISA) identified ten and nine
metabolites, respectively, five of which overlapped. In contrast,
principal component analysis (PCA) did not generate any
pseudospectra with robust metabomatching, likely because
leading components explain variation driven by many
metabolites.
While ACP is designed to pick up individual metabolites with
at least two (nonproximal) features in their spectrum (or those
of metabolite pairs whose concentrations are coupled), ISA is
able to generate modules where many features exhibit coherent
variation, yet potentially only over a subset of samples. We
believe that this may be particularly useful when integrating data
from a heterogeneous set of samples (e.g., including those from
diseased or medicated subpopulations).
One interesting property of our modular approach is that the
feature sets identified by ACP or ISA do not need to match
perfectly with those of the reference spectrum of the
corresponding compound. Indeed, the two ACP signatures
matching glucose each only cover four and jointly six of the nine
glucose peaks, while the ISA module with the best match to
glucose includes seven of its peaks. Adding the “missing” peaks
in our pseudoquantification slightly reduced the correlation with
serum glucose, indicating there is a marginal improvement in the
pseudoquantification using ppm positions only from the
multiplets found by our algorithms rather than the database.
Further work will be needed to substantiate this observation.
Another interesting aspect of our approach is that modular
feature sets may match multiple compounds. Our current
implementation of metabomatching allows simultaneous
identification of up to two compounds. Indeed, our finding
that ISA picked up a module whose signature mapped well to
ethanol and its specific metabolic product ethyl glucuronide
demonstrated the potential power of ISA to identify metabolite
pairs within the same pathway. Moreover, the strong correlation
of this module with the alcohol abuse marker CDT was likely
driven by the fact that ISA can extract context specific
covariance, which in this case is strongest in samples with
particularly high alcohol consumption. This module also
highlighted that using the relevant chemical shifts found by
the module rather than all shifts from the reference database can
lead to more accurate pseudoquantification of the underlying
metabolites, due to different contribution of shifts specific to the
experimental conditions in the complex urine spectra.
Extending metabomatching beyond compound pairs is
challenging due to the large number of possible trios and higher
order combinations, but could be feasible in future work, for
example by using metabolic pathway information to limit the
number of relevant metabolite combinations to test.
A critical element of our analysis was to transform the
signatures generated by the different methods into a universal
format (i.e., z-scores) as input for our metabomatching tool that
we previously developed for the analysis of feature signatures
generated by regression on external variables. Indeed, being able
to query both internal and external signatures of large-scale
NMR data against a reference data set of known spectra from
individual metabolites is pivotal for exploring new methods
dissecting the auto- and cross-correlation structure for
integrative analyses.
In conclusion, we believe that our study using fewer than 1000
samples gives ample evidence for the potential of automated
analysis of large-scale NMR data, and that increased sample sizes
are likely to result in further identifications and more accurate
pseudoquantifications of individual metabolites. To this end, our
analysis software, metabomodules, is made publicly available on
GitHub https://github.com/BergmannLab/metabomodules-
docker.
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